<DOC>
	<DOC>NCT02272556</DOC>
	<brief_summary>Patients will undergo magnetic resonance spectroscopy (MRS) scanning to noninvasively measure intracerebral and plasma metabolite levels at baseline and following 2 and 4 hours of hyperglycemia. Subjects will also undergo a lumbar puncture at a separate occasion to assess cerebrospinal fluid levels of metabolites.</brief_summary>
	<brief_title>Investigating the Role of the Polyol Pathway in the Central Nervous System</brief_title>
	<detailed_description />
	<mesh_term>Hyperglycemia</mesh_term>
	<criteria>Type 2 DM with HbA1C treated with metformin, sulfonylurea, insulin, or combination OR agematched, nondiabetic obese (BMI &gt; 30 kg/m^2) OR agematched lean, healthy control subjects (BMI &lt; 25 kg/m^2) Age 1855 BMI 1845 kg/m^2 Creatinine &gt; 1.5 mg/dL Hgb &lt; 10 mg/dL ALT &gt; 2.5 x ULN Untreated thyroid disease Uncontrolled Hypertension Known Neurological Disorders Untreated Psychiatric Disorders Malignancy Bleeding Disorders Smoking Current or recent steroid use in last 3 months Illicit drug use Pregnancy, actively seeking pregnancy, or breastfeeding Inability to enter MRI/MRS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>